Literature DB >> 23782027

β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis.

Frederic Tissot1, Frederic Lamoth, Philippe M Hauser, Christina Orasch, Ursula Flückiger, Martin Siegemund, Stefan Zimmerli, Thierry Calandra, Jacques Bille, Philippe Eggimann, Oscar Marchetti.   

Abstract

RATIONALE: Life-threatening intraabdominal candidiasis (IAC) occurs in 30 to 40% of high-risk surgical intensive care unit (ICU) patients. Although early IAC diagnosis is crucial, blood cultures are negative, and the role of Candida score/colonization indexes is not established.
OBJECTIVES: The aim of this prospective Fungal Infection Network of Switzerland (FUNGINOS) cohort study was to assess accuracy of 1,3-β-d-glucan (BG) antigenemia for diagnosis of IAC.
METHODS: Four hundred thirty-four consecutive adults with abdominal surgery or acute pancreatitis and ICU stay 72 hours or longer were screened: 89 (20.5%) at high risk for IAC were studied (68 recurrent gastrointestinal tract perforation, 21 acute necrotizing pancreatitis). Diagnostic accuracy of serum BG (Fungitell), Candida score, and colonization indexes was compared.
MEASUREMENTS AND MAIN RESULTS: Fifty-eight of 89 (65%) patients were colonized by Candida; 29 of 89 (33%) presented IAC (27 of 29 with negative blood cultures). Nine hundred twenty-one sera were analyzed (9/patient): median BG was 253 pg/ml (46-9,557) in IAC versus 99 pg/ml (8-440) in colonization (P < 0.01). Sensitivity and specificity of two consecutive BG measurements greater than or equal to 80 pg/ml were 65 and 78%, respectively. In recurrent gastrointestinal tract perforation it was 75 and 77% versus 90 and 38% (Candida score ≥ 3), 79 and 34% (colonization index ≥ 0.5), and 54 and 63% (corrected colonization index ≥ 0.4), respectively. BG positivity anticipated IAC diagnosis (5 d) and antifungal therapy (6 d). Severe sepsis/septic shock and death occurred in 10 of 11 (91%) and 4 of 11 (36%) patients with BG 400 pg/ml or more versus 5 of 18 (28%, P = 0.002) and 1 of 18 (6%, P = 0.05) with BG measurement less than 400 pg/ml. β-Glucan decreased in IAC responding to therapy and increased in nonresponse.
CONCLUSIONS: BG antigenemia is superior to Candida score and colonization indexes and anticipates diagnosis of blood culture-negative IAC. This proof-of-concept observation in strictly selected high-risk surgical ICU patients deserves investigation of BG-driven preemptive therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23782027     DOI: 10.1164/rccm.201211-2069OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  66 in total

1.  Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors.

Authors:  P Pini; C Bettua; C F Orsi; C Venturelli; F Forghieri; S Bigliardi; L Faglioni; F Luppi; L Serio; M Codeluppi; M Luppi; C Mussini; M Girardis; Elisabetta Blasi
Journal:  Infection       Date:  2015-10-16       Impact factor: 3.553

2.  What's new in antimicrobial use and resistance in critically ill patients?

Authors:  Matteo Bassetti; David P Nicolau; Thierry Calandra
Journal:  Intensive Care Med       Date:  2013-12-18       Impact factor: 17.440

3.  Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis.

Authors:  Philippe Montravers; Herve Dupont; Philippe Eggimann
Journal:  Intensive Care Med       Date:  2013-10-24       Impact factor: 17.440

Review 4.  Invasive candidiasis in critical care setting, updated recommendations from "Invasive Fungal Infections-Clinical Forum", Iran.

Authors:  Ashraf Elhoufi; Arezoo Ahmadi; Amir Mohammad Hashem Asnaashari; Mohammad Ali Davarpanah; Behrooz Farzanegan Bidgoli; Omid Moradi Moghaddam; Mohammad Torabi-Nami; Saeed Abbasi; Malak El-Sobky; Ali Ghaziani; Mohammad Hossein Jarrahzadeh; Reza Shahrami; Farzad Shirazian; Farhad Soltani; Homeira Yazdinejad; Farid Zand
Journal:  World J Crit Care Med       Date:  2014-11-04

5.  Intra-abdominal candidiasis: it's still a long way to get unquestionable data.

Authors:  Philippe Montravers; Olivier Leroy; Christian Eckmann
Journal:  Intensive Care Med       Date:  2015-06-19       Impact factor: 17.440

Review 6.  Management of invasive candidiasis in nonneutropenic ICU patients.

Authors:  Emmanuel Weiss; Jean-François Timsit
Journal:  Ther Adv Infect Dis       Date:  2014-10

7.  The EMPIRICUS trial-the final nail in the coffin of empirical antifungal therapy in the intensive care unit?

Authors:  Michael Osthoff; Nina Khanna; Martin Siegemund
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

8.  Appropriate Treatment of Invasive Candidiasis in ICU: Timing, Colonization Index, Candida Score & Biomarkers, Towards de-Escalation?

Authors:  Francesco Giuseppe De Rosa; Silvia Corcione; Giorgia Montrucchio; Luca Brazzi; Giovanni Di Perri
Journal:  Turk J Anaesthesiol Reanim       Date:  2016-12-01

Review 9.  Invasive Candida Infections in the ICU: Diagnosis and Therapy.

Authors:  Péter Hankovszky; Domokos Társy; Nándor Öveges; Zsolt Molnár
Journal:  J Crit Care Med (Targu Mures)       Date:  2015-11-10

Review 10.  Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later.

Authors:  Philippe Eggimann; Didier Pittet
Journal:  Intensive Care Med       Date:  2014-06-17       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.